Navigation Links
Quest Diagnostics to Speak at Wachovia Securities 2008 Healthcare Conference
Date:1/29/2008

MADISON, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Wachovia Securities 2008 Healthcare Conference on Wednesday, January 30, 2008, at the Langham Hotel, Boston, Massachusetts. The Quest Diagnostics presentation is scheduled to begin at 8:00 a.m. Eastern Time.

During the conference, the company will reaffirm its 2007 guidance for revenues of between $6.6 billion and $6.7 billion and earnings per diluted share from continuing operations of between $2.84 and $2.91, before $0.04 per share in special charges recorded in the first quarter of 2007.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://www.wsw.com/webcast/wa48/dgx and to the public on http://www.questdiagnostics.com. In addition, the archived webcast will be available immediately following the presentation and will remain available until February 29, 2008.

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: http://www.questdiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business" in Part I, Item 1, "Risk Factors" and "Cautionary Statement for Purposes of the 'Safe Harbor' Provisions of the Private Securities Litigation Reform Act of 1995" in Item I, Part 1A, "Legal Proceedings" in Part I, Item 3, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 and "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A in the Quest Diagnostics 2006 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's 2007 Quarterly Reports on Form 10-Q and other items throughout the Form 10-K and the Company's 2007 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
2. The 7 Key Questions About the Schwarzenegger/Nunez Health Care Compromise
3. LifeQuest Announces End of Immunity Health Challenge Contest
4. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
5. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
6. Study Questions Dead-End Cancer Clinical Trials
7. 6 Years Later, 9/11 Health Questions Linger
8. U.S. Physicians Question Presidential Candidates
9. RFID Implant Cancer Questions Concern Patients
10. Study Questions Genetic Screening for Treatable Diseases
11. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... 24, 2017 , ... Emmanuel College is introducing enhancements to its ... Beginning in the fall of 2017, Emmanuel’s program will allow registered nurses (RN)s to ... months and for as little as $14,528. These changes will enable nurses to complete ...
(Date:4/24/2017)... ... ... The Santana Telehealth Project was honored with the 2017 ATA Humanitarian Award. ... annual conference, on April 23 in Orlando, FL. , “I am proud that ATA ... the poor and underserved in other parts of the world,” said Jonathan Linkous, CEO ...
(Date:4/24/2017)... CO (PRWEB) , ... April 24, 2017 , ... ... American Educational Research Association’s Outstanding Public Communication of Education Research Award. The award ... public, including education communities. It recognizes a scholar who has demonstrated the capacity ...
(Date:4/24/2017)... ... 2017 , ... The California Dental Association Foundation’s two-day volunteer dental clinic, ... during the April 22-23 event at the San Mateo Event Center. , In ... care, CDA Cares educates the public and policymakers about the importance of good oral ...
(Date:4/24/2017)... Houston (PRWEB) , ... April 24, 2017 , ... The ... an innovative technology that allows anyone, anywhere to track their cognitive health, and share ... to check their own brain health on the museum's website. , BrainCheck founder, Dr. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: